Driving assessment

Evidence for a genetically driven metabolomic signature in actively inflamed Crohn’s disease

  • Lee, JC et al. A genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility to Crohn’s disease. Nat. Broom. 49262-268 (2017).

    Article

    Google Scholar

  • Khor, B. et al. Genetics and pathogenesis of inflammatory bowel disease. Nature 474307-317 (2011).

    CASE
    Article

    Google Scholar

  • Amiot, A. & Peyrin, BL Current, new, and future biological agents on the horizon for the treatment of inflammatory bowel disease. The. Adv. Gastroenterol. 866–82 (2015).

    Article

    Google Scholar

  • Shicho, R. et al. Quantitative metabolomic profiling of serum, plasma and urine by 1H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J. Proteome Res. 113344–3357 (2012).

    CASE
    Article

    Google Scholar

  • Dawiskiba, T. et al. Serum and urine metabolomic fingerprinting in the diagnosis of inflammatory bowel disease. World J. Gastroenterol. 20163–174 (2014).

    CASE
    Article

    Google Scholar

  • Moschen, AR, Tilg, H. & Raine, T. IL-12, IL-23, and IL-17 in IBD: Immunobiology and Therapeutic Targeting. Nat. Rev. Gastroenterol. Hepatol. 16185-196 (2019).

    CASE
    Article

    Google Scholar

  • Ruedi, R. et al. Metabomatching: Using genetic association to identify metabolites in proton NMR spectroscopy. PLOS calculation. Biol. 13e1005839 (2017).

    Article

    Google Scholar

  • Ashton, JJ et al. Analysis and hierarchical clustering of blood findings prior to diagnosis in pediatric inflammatory bowel disease. Inflamm. Intestine Say. 26469–475 (2020).

    PubMed

    Google Scholar

  • Ashton, JJ et al. Genetic sequencing of pediatric patients identifies mutations in monogenic inflammatory bowel disease genes that result in distinct clinical phenotypes. Clin. Transl. Gastroenterol. 11 (2020). Available at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145023/. Accessed May 9, 2021.

  • Ashton, JJ et al. TTC7A variants previously described as causing enteropathy are observed on a single haplotype and appear non-pathogenic in pediatric patients with inflammatory bowel disease. J. Clin. Immunol. 40245-247 (2020).

    Article

    Google Scholar

  • Mosotto, E. et al. GenePy—A score for estimating the pathogenicity of genes in individuals using next-generation sequencing data. BMC Bioinform. 20254 (2019).

    CASE
    Article

    Google Scholar

  • Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Broom. 46310–315 (2014).

    CASE
    Article

    Google Scholar

  • Itane, Y. et al. The human genetic damage index as a gene-level approach to prioritizing exome variants. proc. Natl. Acad. Science. UNITED STATES 11213615–13620 (2015).

    ADS
    CASE
    Article

    Google Scholar

  • Cloarec, O. et al. Statistical total correlation spectroscopy: an exploratory approach for the identification of latent biomarkers from metabolic 1H NMR datasets. Anal. Chem. 771282–1289 (2005).

    CASE
    Article

    Google Scholar

  • Health C for D and R. Review criteria for evaluating C-reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), and cardiac C-reactive protein (cCRP) assays—Tips for industry and FDA staff. US Food and Drug Administration (2019). Available at https://www.fda.gov/regulatory-information/search-fda-guidance-documents/review-criteria-assessment-c-reactive-protein-crp-high-sensitivity-c-reactive-protein-hscrp-and. Accessed April 20, 2021.

  • World Health Organization. C-reactive protein concentrations as a marker of inflammation or infection for the interpretation of biomarkers of micronutrient status. Vitamin and Mineral Nutrition Information System. Available at WHO/NMH/NHD/EPG/14.7; http://apps.who.int/iris/bitstream/10665/133708/1/WHO_NMH_NHD_EPG_14.7_eng.pdf?ua=1 (2014).

  • Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and gene list conversions (2019 update). Nucleic Acids Res. 47W191–W198 (2019).

    CASE
    Article

    Google Scholar

  • Toussirot, E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm. Allergy drugs target Discontin. 11159-168 (2012).

    CASE
    Article

    Google Scholar

  • Benson, JM et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for the treatment of immune-mediated disorders. AcM 3535–545 (2011).

    Article

    Google Scholar

  • Connelly, MA et al. Inflammatory glycoproteins in cardiometabolic disorders, autoimmune diseases and cancer. Clin. Chem. Deed 459177–186 (2016).

    CASE
    Article

    Google Scholar

  • Bell, J.D. et al. Assignment of resonances for “acute phase” glycoproteins in high-resolution proton NMR spectra of human blood plasma. FEBS Lett. 215311-315 (1987).

    CASE
    Article

    Google Scholar

  • Otvos, J.D. et al. GlycA: a composite nuclear magnetic resonance biomarker of systemic inflammation. Clin. Chem. 61714-723 (2015).

    CASE
    Article

    Google Scholar

  • Fuertes-Martin, R. et al. Characterization of 1H NMR plasma glycoproteins as a new strategy to identify inflammatory patterns in rheumatoid arthritis. J. Proteome Res. 173730–3739 (2018).

    Article

    Google Scholar

  • Connelly, MA et al. Differences in GlycA and lipoprotein particle parameters may help distinguish acute kawasaki illness from other febrile illnesses in children. BMC Pediatr. 16151 (2016).

    Article

    Google Scholar

  • Ballout, RA & Remaley, AT GlycA: A novel biomarker for systemic inflammation and cardiovascular disease (CVD) risk assessment. J. Lab. Accurate. Med. 5 (2020). Available at https://jlpm.amegroups.com/article/view/5567. Accessed July 6, 2022.

  • Macy, EM, Hayes, TE & Tracy, RP Variability in C-reactive protein measurement in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 4352–58 (1997).

    CASE
    Article

    Google Scholar

  • Duprez, DA et al. Comparison of the predictive value of GlycA and other inflammatory biomarkers for total mortality, incident cardiovascular events, non-cardiovascular and non-cancer inflammatory events, and total cancer events. Clin. Chem. 621020-1031 (2016).

    CASE
    Article

    Google Scholar

  • Gabay, C. & Kushner, I. Acute phase proteins and other systemic responses to inflammation. N.Engl. J.Med. 340448–454 (1999).

    CASE
    Article

    Google Scholar

  • Lot, BC et al. Branched-chain amino acids are new biomarkers for the discrimination of metabolic well-being. Metabolism 62961–969 (2013).

    CASE
    Article

    Google Scholar

  • Libert, DM, Nowacki, AS & Natowicz, MR Metabolomic analysis of obesity, metabolic syndrome, and type 2 diabetes: Amino acid and acylcarnitine levels change across a metabolic wellness spectrum. PeerJ 6e5410 (2018).

    Article

    Google Scholar

  • Le Roy, CI et al. Dissect the role of gut microbiota and diet on visceral fat mass accumulation. Science. representing 99758 (2019).

    ADS
    Article

    Google Scholar

  • Ashton, JJ et al. Deleterious genetic variation through the NOD signaling pathway is associated with reduced transcription of NFKB signaling and upregulation of alternative inflammatory transcripts in childhood inflammatory bowel disease. Inflamm. Intestine Say. 28912–922 (2022).

    Article

    Google Scholar

  • Coelho, T. et al. Immunological profiling of pediatric inflammatory bowel disease using unsupervised machine learning. J. Pediatr. Gastroenterol. Nutr. 70833–840 (2020).

    CASE
    Article

    Google Scholar

  • Das, J. et al. A critical role for NF-κB in Gata3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol. 245–50 (2001).

    CASE
    Article

    Google Scholar

  • Atreya, I., Atreya, R. & Neurath, MF NF-κB in inflammatory bowel disease. J. Trainee. Med. 263591-596 (2008).

    CASE
    Article

    Google Scholar

  • Liu, T. et al. NF-κB signaling in inflammation. Signal transducer. Target. The. 21–9 (2017).

    CASE

    Google Scholar

  • Khader, South Africa et al. IL-23 and IL-17 in the establishment of protective lung CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat. Immunol. 8369-377 (2007).

    CASE
    Article

    Google Scholar

  • Ueno, A. et al. Th17 plasticity and its changes associated with inflammatory bowel disease. World J. Gastroenterol. 2112283–12295 (2015).

    CASE
    Article

    Google Scholar

  • Glass, J. et al. Analysis of IL12B gene variants in inflammatory bowel disease. PLOS ONE sevene34349 (2012).

    ADS
    CASE
    Article

    Google Scholar

  • Sandborn, WJ et al. Induction and maintenance therapy of ustekinumab in refractory Crohn’s disease. N.Engl. J.Med. 3671519-1528 (2012).

    CASE
    Article

    Google Scholar

  • Lee, HW et al. The correlation of serum IL-12B expression with disease activity in patients with inflammatory bowel disease. Medicine (Baltimore) 95e3772 (2016).

    CASE
    Article

    Google Scholar

  • Eftychi, C. et al. Temporally distinct functions of the cytokines IL-12 and IL-23 lead to chronic inflammation of the colon in response to an altered gut barrier. Immunity 51367–380.e4 (2019).

    CASE
    Article

    Google Scholar

  • Ritchie, South Carolina et al. The biomarker GlycA is associated with chronic inflammation and predicts the long-term risk of serious infection. System cell 1(4), 293–301. https://doi.org/10.1016/j.cels.2015.09.007 (2015).

    CASE
    Article
    PubMed

    Google Scholar

  • Dierckx, T. et al. GlycA, a nuclear magnetic resonance spectroscopy measure for protein glycosylation, is a viable biomarker for disease activity in IBD. J. Crohns colitis 13(3), 389–394. https://doi.org/10.1093/ecco-jcc/jjy162 (2019).

    Article
    PubMed

    Google Scholar